Open AccessA functionally significant SNP in TP53 and breast cancer risk in African-American women
Author(s) -
Maureen E. Murphy,
Song Liu,
Song Yao,
Dezheng Huo,
Liu Q,
Sonia Dolfi,
Kim M. Hirshfield,
Chi Chen Hong,
Qiang Hu,
Andrew F. Olshan,
Temidayo O. Ogundiran,
Clement Adebamowo,
Susan M. Domchek,
Katherine L. Nathanson,
Barbara Nemesure,
Stefan Ambs,
William J. Blot,
Yang Feng,
Esther M. John,
Leslie Bernstein,
Zheng Wang,
Jennifer J. Hu,
Regina G. Ziegler,
Sarah J. Nyante,
Sue A. Ingles,
Michael F. Press,
Sandra L. Deming,
Jorge L. Rodriguez-Gil,
Christopher A. Haiman,
Olufunmilayo I. Olopade,
Kathryn L. Lunetta,
Julie R. Palmer,
Christine B. Ambrosone
Publication year - 2017
Publication title -
npj breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.746
H-Index - 21
ISSN - 2374-4677
DOI - 10.1038/s41523-017-0007-9
Subject(s) - breast cancer , odds ratio , allele , oncology , snp , biology , single nucleotide polymorphism , population , medicine , confidence interval , case control study , logistic regression , cancer , genetics , etiology , genotype , demography , gene , environmental health , sociology
A coding region polymorphism exists in the TP53 gene (Pro47Ser; rs1800371) in individuals of African descent, which reduces p53 tumor suppressor function in a mouse model. It has been unclear whether this functionally significant polymorphism alters cancer risk in humans. This analysis included 6907 women with breast cancer and 7644 controls from the AMBER, ROOT, and AABC consortia. We used multivariable logistic regression to estimate associations between the TP53 Pro47Ser allele and overall breast cancer risk. Because polymorphisms in TP53 tend to be associated with cancer risk in pre-menopausal women, we also limited our analyses to this population in the AMBER and ROOT consortia, where menopausal status was known, and conducted a fixed effects meta-analysis. In an analysis of all women in the AMBER, ROOT, and AABC consortia, we found no evidence for association of the Pro47Ser variant with breast cancer risk. However, when we restricted our analysis to only pre-menopausal women from the AMBER and ROOT consortia, there was a per allele odds ratio of 1.72 (95% confidence interval 1.08–2.76; p -value = 0.023). Although the Pro47Ser variant was not associated with overall breast cancer risk, it may increase risk among pre-menopausal women of African ancestry. Following up on more studies in human populations may better elucidate the role of this variant in breast cancer etiology. However, because of the low frequency of the polymorphism in women of African ancestry, its impact at a population level may be minimal.